1. Mortality according to CD4 count at start of combination antiretroviral therapy among HIV positive patients followed for up to 15 years after start of treatment: collaborative cohort study
- Author
-
May, Margaret T, Vehreschild, Jorg-Janne, Trickey, Adam, Obel, Niels, Reiss, Peter, Bonnet, Fabrice, Mary-Krause, Murielle, Samji, Hasina, Cavassini, Matthias, Gill, Michael John, Shepherd, Leah C, Crane, Heidi M, d'Arminio Monforte, Antonella, Burkholder, Greer A, Johnson, Margaret M, Sobrino-Vegas, Paz, Domingo, Pere, Zangerle, Robert, Justice, Amy C, Sterling, Timothy R, Miró, José M, Sterne, Jonathan A C, Antiretroviral Therapy Cohort Collaboration (ART-CC), University of Bristol [Bristol], Universität zu Köln = University of Cologne, University of Copenhagen = Københavns Universitet (UCPH), University of Amsterdam [Amsterdam] (UvA), Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Université Bordeaux Segalen - Bordeaux 2, CHU Bordeaux [Bordeaux], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Université de Lausanne = University of Lausanne (UNIL), University of Calgary, UCL Medical School, University of Washington [Seattle], 'San Paolo' Hospital, University of Alabama [Tuscaloosa] (UA), Royal Free London NHS Foundation Trust, Instituto Salud Carlos III, Universitat Autònoma de Barcelona (UAB), Universität Innsbruck [Innsbruck], Yale University [New Haven], VA Connecticut Healthcare System, Vanderbilt University [Nashville], Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Medical Research Council (Reino Unido), Department for International Development (Reino Unido), National Institute for Health Research (Reino Unido), Agence Nationale de Recherches sur le sida et les hépatites virales (Francia), Institut National de la Santé et de la Recherche Médicale (Francia), Ministère de la Santé (Francia), Ministero della Salute (Italia), Ministerio de Sanidad (España), Swiss National Science Foundation, Ministerio de Ciencia e Innovación (España), Red de Investigación Cooperativa en Investigación en Sida (España), Stichting HIV Monitoring (Netherlands), Unión Europea, National Institutes of Health (Estados Unidos), NIH - National Institute on Alcohol Abuse and Alcoholism (NIAAA) (Estados Unidos), United States Department of Veterans Affairs, Michael Smith Foundation for Health Research, Canadian Institutes of Health Research, Veterans Health Administration, Unión Europea. Comisión Europea. 7 Programa Marco, Government of Alberta (Canadá), Government of Columnia (Estados Unidos), Government of the United Kingdom, Abbott, Gilead Sciences (Spain), Tibotec-Upjohn, ViiV Healthcare, GlaxoSmithKline, Pfizer, Bristol-Myers Squibb, Roche, Boehringer Ingelheim Fonds, Merck, Sharp & Dohme, HAL UPMC, Gestionnaire, Antiretroviral Therapy Cohort Collaboration (ART-CC), Boulle, A., Stephan, C., Miro, JM., Cavassini, M., Chêne, G., Costagliola, D., Dabis, F., Monforte£££Antonella D'Arminio£££ AD., Del Amo, J., Van Sighem, A., Fätkenheuer, G., Gill, J., Guest, J., Haerry, DH., Hogg, R., Justice, A., Shepherd, L., Obel, N., Crane, H., Smith, C., Reiss, P., Saag, M., Sterling, T., Teira, R., Williams, M., Zangerle, R., Sterne, J., May, M., Ingle, S., Trickey, A., Universität zu Köln, University of Copenhagen = Københavns Universitet (KU), Université de Lausanne (UNIL), AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, Global Health, and Universitat de Barcelona
- Subjects
0301 basic medicine ,Male ,Integrase inhibitor ,HIV Infections ,Kaplan-Meier Estimate ,Cohort Studies ,0302 clinical medicine ,Cohort collaboration ,030212 general & internal medicine ,Lymphocytes ,[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,education.field_of_study ,Reverse-transcriptase inhibitor ,Relative survival ,Mortality rate ,Antiretrovirals ,Middle Aged ,3. Good health ,Antiretroviral therapy ,Infectious Diseases ,Anti-Retroviral Agents ,Cohort ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,HIV/AIDS ,Female ,medicine.drug ,Cohort study ,Microbiology (medical) ,Adult ,medicine.medical_specialty ,Adolescent ,Population ,antiretroviral therapy ,CD4 count ,Limfòcits ,03 medical and health sciences ,Young Adult ,Internal medicine ,medicine ,VIH (Virus) ,Humans ,Mortality ,education ,Survival analysis ,business.industry ,HIV (Viruses) ,cohort collaboration ,HIV ,mortality ,Antiretroviral agents ,Surgery ,CD4 Lymphocyte Count ,030104 developmental biology ,Morbiditat ,Morbidity ,business - Abstract
The strong association of CD4 count at start of combination therapy with subsequent survival in HIV-infected patients diminished during the first 5 years of treatment. After 5 years, lower baseline CD4 counts were not associated with higher mortality., Background. CD4 count at start of combination antiretroviral therapy (ART) is strongly associated with short-term survival, but its association with longer-term survival is less well characterized. Methods. We estimated mortality rates (MRs) by time since start of ART (
- Published
- 2016
- Full Text
- View/download PDF